MACULAR NEURODEGENERATIVE AND VASCULAR CHANGES ON OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN SICKLE CELL DISEASE ARE NOT RELATED TO ITS OCULAR AND SYSTEMIC COMPLICATIONS

镰状细胞病患者的黄斑神经退行性变和血管变化在光学相干断层血管造影中表现为与眼部和全身并发症无关。

阅读:1

Abstract

PURPOSE: To evaluate macular abnormalities in sickle cell disease with optical coherence tomographic angiography and to determine associations with sickle cell retinopathy (SCR) and clinical and laboratory characteristics. METHODS: Complete ophthalmic examination was performed in consecutive patients with sickle cell disease (HbSS, HbSC, HbSβ 0 , or HbSβ + genotype), including fundoscopy and macular spectral-domain optical coherence tomography/optical coherence tomographic angiography scans. Sickle cell retinopathy stage was based on fundoscopic examination (without fluorescein angiography) instead of the Goldberg classification because fluorescein angiography was only used in case of tentative diagnosis. Medical/ophthalmological history and hematologic characteristics were retrieved from medical records. RESULTS: Two hundred and forty-nine eyes of 137 patients were analyzed. The mean age was 33.3 ± 12.4 years (range 15-70 years). Nonproliferative SCR was present in 57 eyes (22.9%) and proliferative SCR in 36 eyes (14.5%). Macular thinning was present in 100 eyes (40.2%) and was associated with lower foveal vessel density of the superficial capillary plexus and deep capillary plexus and with enlargement of the foveal avascular zone area, perimeter, and acircularity index. Age and female sex were associated with lower (para)foveal vessel density in the superficial capillary plexus and deep capillary plexus. No associations were found between SCR presence/severity and macular thinning or vessel density. CONCLUSION: Macular abnormalities were common but did not result in visual impairment. No relation with SCR presence/severity was found. Although optical coherence tomographic angiography imaging is suitable for detecting maculopathy, it appears to have no diagnostic value in identifying patients at risk for SCR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。